No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy

byKathleen Lau

March 18, 2021

in StudyGraphics

Rapid antigen-based home testing reduced SARS-CoV-2 transmission and mortality

RelatedReports

Chronic Disease

Enfortumab vedotin plus pembrolizumab is more effective than platinum-based chemotherapy in metastatic urothelial carcinoma

July 9, 2026

Obstetric scoring systems overestimate cases of severe sepsis

All Specialties

2 Minute Medicine Rewind July 6, 2026

July 7, 2026

Chronic Disease

Allophone home care recipients with terminal cancer may have worse end-of-life outcomes compared to anglophone patients

July 1, 2026

Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening

Chronic Disease

Male sex and hispanic ethnicity are associated with increased risk of early-onset colorectal cancer

June 29, 2026

#VisualAbstract: Salpingo-oophorectomy may reduce short-term risk of breast cancer in women with BRCA1 and BRCA2 variants

#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

Pirtobrutinib is safe and efficacious in the treatment of relapsed or refractory B-cell malignancies (BRUIN Trial)

Parents often unaware of adolescents’ suicidal thoughts

Ketamine infusion significantly reduces depressive symptoms among adolescents with treatment-resistant depression

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy

RELATED REPORTS

Rapid antigen-based home testing reduced SARS-CoV-2 transmission and mortality

#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)

RelatedReports

Recent Reports